Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Nearly all patients with untreated chronic hepatitis C virus (HCV) and all of those with genotype 1 infection whose previous treatment with telaprevir or boceprevir had failed were cured with the oral combination therapy daclatasvir plus sofosbuvir in an open-label study of 211 patients (Sulkowski MS et al. N Engl J Med. doi:10.1056/NEJMoa1306218 [published online January 16, 2014]).
Patients were randomly assigned to receive sofosbuvir for 1 week, then daclatasvir and sofosbuvir for 23 weeks; daclatasvir and sofosbuvir with or without ribavirin for 24 weeks; or daclatasvir plus sofosbuvir, with or without ribavirin, for 12 or 24 weeks.
Slomski A. Combination Oral Therapy Appears Effective in Treating HCV. JAMA. 2014;311(8):790. doi:10.1001/jama.2014.1555